5.20

2.16% +0.11

After Hours: 5.10 -0.10 -1.92%

Aurinia Pharmaceuticals Inc (AUPH)

Overview News Price History Option Chain Why AUPH Down? Discussions Forecast Stock Split

Aurinia Pharmaceuticals Inc stock is currently priced at $5.20, with a 24-hour trading volume of 1.66M. It has seen a +2.16% increased in the last 24 hours and a -3.70% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $5.08 pivot point. If it approaches the $5.28 resistance level, significant changes may occur.

Previous Close:

$5.09

Open:

$5.08

24h Volume:

1.66M

Market Cap:

$738.70M

Revenue:

$175.51M

Net Income/Loss:

$-78.02M

P/E Ratio:

-9.8113

EPS:

-0.53

Net Cash Flow:

$-34.18M

1W Performance:

+3.38%

1M Performance:

-3.70%

6M Performance:

-27.07%

1Y Performance:

-53.57%

1D Range:

$5.07

$5.31

52W Range:

$4.71

$12.43

Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile

Name

Aurinia Pharmaceuticals Inc

Sector

Healthcare (1202)

Industry

Biotechnology (682)

Phone

250-744-2487

Address

4464 Markham Street, Suite 1203, Victoria, BC

Employee

Twitter

@AuriniaPharma

Next Earnings Date

2024-05-02

Latest SEC Filings

AUPH's Discussions on Twitter

Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-04-22	Downgrade	Oppenheimer	Outperform → Perform
May-05-22	Resumed	Cantor Fitzgerald	Overweight
Dec-10-21	Upgrade	Oppenheimer	Perform → Outperform
Oct-28-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-25-21	Reiterated	H.C. Wainwright	Buy
Nov-03-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Initiated	BTIG Research	Buy
May-05-20	Initiated	Cowen	Outperform
Jan-10-20	Initiated	Jefferies	Buy
Dec-16-19	Reiterated	H.C. Wainwright	Buy
Mar-16-18	Reiterated	Cantor Fitzgerald	Overweight
Feb-08-18	Initiated	RBC Capital Mkts	Outperform
Oct-30-17	Reiterated	H.C. Wainwright	Buy
May-18-17	Reiterated	H.C. Wainwright	Buy
Apr-11-17	Initiated	Cantor Fitzgerald	Overweight
Mar-22-17	Reiterated	FBR & Co.	Outperform
Dec-30-16	Reiterated	H.C. Wainwright	Buy
Aug-17-16	Reiterated	H.C. Wainwright	Buy
Jun-30-16	Initiated	H.C. Wainwright	Buy
May-08-15	Initiated	MLV & Co	Buy

View All

Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News

Analog Devices To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday

Benzinga

Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Benzinga

Aurinia Pharmaceuticals (AUPH) Reports Q4 Loss, Tops Revenue Estimates

Zacks Investment Research

Esperion Therapeutics (ESPR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Aurinia Pharmaceuticals (AUPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

Zacks Investment Research

Are Medical Stocks Lagging Aurinia Pharmaceuticals (AUPH) This Year?

Zacks Investment Research

Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data

Aurinia Pharmaceuticals Inc (AUPH) Revenue 2024

AUPH reported a revenue (TTM) of $175.51 million for the quarter ending December 31, 2023, a +30.95% rise year-over-year.

Aurinia Pharmaceuticals Inc (AUPH) Net Income 2024

AUPH net income (TTM) was -$78.02 million for the quarter ending December 31, 2023, a +27.88% increase year-over-year.

Aurinia Pharmaceuticals Inc (AUPH) Cash Flow 2024

AUPH recorded a free cash flow (TTM) of -$34.18 million for the quarter ending December 31, 2023, a +57.18% increase year-over-year.

Aurinia Pharmaceuticals Inc (AUPH) Earnings per Share 2024

AUPH earnings per share (TTM) was -$0.53 for the quarter ending December 31, 2023, a +30.26% growth year-over-year.

Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total
Robertson Stephen P.	EVP, General Counsel	Mar 06 '24	Sale	5.60	57,745	323,372	443,824
Donley Matthew Maxwell	EVP, Ops & Strategy	Mar 06 '24	Sale	5.51	40,665	224,064	584,072
Miller Joseph M	Chief Financial Officer	Mar 06 '24	Sale	5.60	34,811	194,942	495,928
Habig Scott Michael	Chief Commercial Officer	Mar 06 '24	Sale	5.60	17,777	99,551	474,587
Knappertz Volker	EVP, Research and Development	Feb 27 '24	Sale	6.10	4,930	30,073	319,128
Knappertz Volker	EVP, Research and Development	Feb 20 '24	Sale	5.48	25,146	137,800	324,058
Habig Scott Michael	Chief Commercial Officer	Feb 20 '24	Sale	5.48	15,867	86,951	492,364
Jayne David R.W.	Director	May 23 '23	Sale	11.26	8,733	98,334	49,310
MacKay-Dunn R. Hector	Director	May 23 '23	Sale	11.26	4,818	54,251	24,225
Leversage Jill	Director	May 23 '23	Sale	11.26	4,815	54,217	18,528

Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. It has a sales agreement with Cantor Fitzgerald & Co.; and a manufacturing collaboration and services agreement with Lonza Ltd. The company was formerly known as Isotechnika Pharma Inc. and changed its name to Aurinia Pharmaceuticals Inc. in October 2013. Aurinia Pharmaceuticals Inc. was founded in 1993 and is headquartered in Victoria, Canada.